Branch² Intelligence
Dr Reddy's extends slide as semaglutide setback threatens first-mover edge
Key takeaway
Dr Reddy's semaglutide supply disruption erodes first-mover edge in India's GLP-1 market.
- Step 1Dr Reddy's semaglutide supply disruption halts production.
- Step 2Competitors (Sun Pharma, Cipla) fill the gap, gaining market share and pricing power.
- Step 3UK API suppliers face delayed orders and margin pressure as Indian demand shifts.
Source: IN:The Hindu BusinessLine
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.